KarXT shows remarkable safety and efficacy in schizophrenia patients: Lancet
The medication KarXT represents a significant departure from the conventional antipsychotic drugs by targeting muscarinic receptors instead of blocking the D2 dopamine receptors. This novel treatment for schizophrenia has shown remarkable efficacy and tolerability in a recent clinical trial. The outcomes of this study were published in The Lancet journal. The EMERGENT-2 trial, a phase […]